(Q54412418)

29 May 2018

title

Long-term indoramin therapy in congestive heart failure: a double-blind, randomized, parallel placebo-controlled trial. (English)

1 reference

29 May 2018

0 references

1 reference

1 reference

congestive heart failure

1 reference

C V Leier

1

1 reference

29 May 2018

P F Binkley

series ordinal

2

1 reference

29 May 2018

P H Randolph

series ordinal

3

1 reference

29 May 2018

D V Unverferth

series ordinal

4

1 reference

29 May 2018

language of work or name

English

0 references

publication date

1 February 1987

1 reference

29 May 2018

Journal of the American College of Cardiology

published in

1 reference

29 May 2018

volume

9

1 reference

29 May 2018

issue

2

1 reference

29 May 2018

page(s)

426-432

1 reference

29 May 2018

CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Plasma norepinephrine in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Central and peripheral contribution to the antihypertensive action of indoramin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Differential blockade of alpha-adrenoceptors by indoramin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

The cardiovascular effects of centrally and peripherally administered indoramin in conscious rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Indoramin-prolongation of repolarization time, a mechanism of bradycardia in man?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

The reversal of experimental cardiac arrhythmias by indoramin (Wy 21901).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Electrophysiological effects of alpha-adrenoceptor stimulation in normal and ischemic myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Central sympathetic reactivity inhibited by indoramin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

The effect of prazosin, indoramin and phentolamine on sympathetic nerve activity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Investigation into Mechanism of Lack of Reflex Tachycardia in Response to Hypotensive Action of Indoramin in Dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Cardiovascular effects of indoramin in man--a dose ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Clinical evaluation of indoramin, a new antihypertensive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

α-Adrenoreceptor Blockade with Indoramin in Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Acute hemodynamic and hormonal response to indoramin in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Development of pharmacodynamic tolerance to prazosin in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Clonidine in congestive heart failure: a vasodilator with negative inotropic effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2887%2980399-6

7 January 2021

10.1016/S0735-1097(87)80399-6

Identifiers

DOI

1 reference

29 May 2018

1 reference

29 May 2018